Search
Acoramidis
go.drugbank.com/drugs/DB17999ApprovedInvestigationalAcoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis. Similar to the previously developed tafamidis, acoramidis is used to stabilize TTR in its tetrameric form, preventing the formatio...
Dienogest
go.drugbank.com/drugs/DB09123ApprovedInvestigationalIt is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in United States and Europe however it is not available in the US by itself. … In Europe, Australia, Malaysia, Singapore and Japan, dienogest single therapy is an approved treatment for endometriosis to alleviate painful symptoms of endometriosis and reduce endometriotic lesions
Methohexital
go.drugbank.com/drugs/DB00474ApprovedAn intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.
Talbutal
go.drugbank.com/drugs/DB00306ApprovedIllicitTalbutal, also called 5-allyl-5-sec-butylbarbituric acid, is a barbiturate with a short to intermediate duration of action. Talbutal is a schedule III drug in the U.S.
Carbidopa
go.drugbank.com/drugs/DB00190ApprovedInvestigationalCarbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate. It potently inhibits aromatic amino acid decarboxylase (DDC) and due to its chemical properties, it does not cross the blood-brain barri...
Acetrizoic acid
go.drugbank.com/drugs/DB09347ApprovedWithdrawnAcetrizoic acid presents the molecular formula of 3-acetamidol-2,4,6-triiodobenzoic acid and it is the first monomeric ionic compound used as an X-ray contrast agent. It was first synthesized by Wallingford in 1953 and it was filled in t...
Sumatriptan
go.drugbank.com/drugs/DB00669ApprovedInvestigational[L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.
Cyclopentamine
go.drugbank.com/drugs/DB08999ApprovedWithdrawnCyclopentamine was an over the counter treatment for nasal congestion in Europe and Australia.
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigationalUse (CHMP) recommended maralixibat be granted marketing authorization for the treatment of cholestatic pruritus in patients with Alagille syndrome:[L43547] it was granted marketing authorization in Europe